Molecular and Translational Oncology Research

分子和转化肿瘤学研究

• 批准号: 9280411
• 负责人: JOHN BLENIS
• 金额: $ 27.23万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-01 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9280411
• 关键词: Molecular; Research; oncology

ABSTRACT The past decade, an explosion of research and technological achievements in molecular oncology and genomics have offered an unprecedented opportunity to transform patient care. This shift in the traditional cancer research paradigm, demands for more sophisticated skills to be acquired by cancer scientists. We are requesting support via a new T32 training grant for the research training of four postdoctoral fellows in Molecular and Translational Oncology Research (MTOR) at Weill Cornell Medicine (WCM). WCM will provide funding for an additional fifth training slot. The objective of this program is to recruit the best possible candidates with a solid foundation in basic science and train them in molecular and translational oncology so that they can apply their knowledge to address important clinically unmet needs in the prevention, diagnosis, and treatment of cancer patients. MTOR trainees will receive program support for two years during which they will follow a structured and rigorous postdoctoral training path. The MTOR program is a joint effort of 17 outstanding WCM preceptors and co-mentors, and a dense network of clinical collaborators, who are international leaders in their respective fields. Trainees will further profit from the leveraging of institutional resources such as the Sandra and Edward Meyer Cancer Center and Weill Cornell's Clinical and Translational Science Center (CTSC). MTOR's highly personalized training plan will include 1) individual development plans and customized workplans; 2) rigorous translationally focused research training; 3) hands-on experience in cutting-edge methodologies; and 4) a comprehensive curriculum of innovative core and ancillary skill acquisition workshops, including writing, leadership, communication, and entrepreneurial perspectives. We anticipate a pool of at least 300 candidates. We have assembled an outstanding roster of external and internal advisory committee members with the mandate to evaluate the program and provide specific recommendations to improve its efficiency. MTOR has a strong diversity focus and through its rigorous, structured and highly personalized curriculum, seeks to train the future leaders in translational cancer research in the USA.

抽象的 过去十年，分子肿瘤学和基因组学领域的研究和技术成果呈爆炸式增长。 为改变患者护理提供了前所未有的机会。传统癌症研究范式的转变 要求癌症科学家掌握更复杂的技能。我们正在请求通过新 T32 提供支持 为四名分子和转化肿瘤学研究博士后研究员的研究培训提供培训补助金 （MTOR）在威尔康奈尔医学（WCM）。 WCM 将为额外的第五个培训名额提供资金。这 该计划的目标是招募具有扎实基础科学基础的最佳候选人并进行培训 他们从事分子和转化肿瘤学研究，以便他们能够运用自己的知识来解决重要的临床问题 癌症患者的预防、诊断和治疗方面的未满足的需求。 MTOR 学员将收到课程 为期两年的支持，在此期间他们将遵循结构化且严格的博士后培训路径。 MTOR 该计划是 17 名杰出的 WCM 导师和共同导师的共同努力，以及一个密集的临床网络 合作者，他们是各自领域的国际领导者。学员将进一步受益于杠杆作用 机构资源，例如桑德拉和爱德华迈耶癌症中心以及威尔康奈尔的临床和 转化科学中心（CTSC）。 MTOR 高度个性化的培训计划将包括 1) 个人 发展计划和定制工作计划； 2）严格的以转化为重点的研究培训； 3）动手实践 尖端方法学方面的经验； 4）创新核心和辅助技能的综合课程 收购研讨会，包括写作、领导力、沟通和创业观点。我们预计 至少有 300 名候选人。我们组建了一支优秀的外部和内部顾问委员会名单 成员的任务是评估该计划并提供具体建议以提高其效率。 MTOR 非常注重多元化，并通过其严格、结构化和高度个性化的课程，力求 培养美国转化癌症研究的未来领导者。